Myxedema Coma or Crisis Workup
- Author: Mohsen S Eledrisi, MD, FACP, FACE; Chief Editor: George T Griffing, MD more...
Laboratory studies are important to confirm the diagnosis of myxedema coma. However, if the condition is suspected, treatment should be started immediately without waiting for the results.
- Thyroid function tests
- TSH is elevated in most patients indicating a primary thyroid disorder
- Free T4 and free T3 levels are low
- A low or normal TSH level with low levels of free T4 and free T3 may indicate that the disorder is due to pituitary or hypothalamic dysfunction
- Assessment of adrenal function should be performed. A random serum cortisol can be obtained; however, the test is only helpful if it’s very low (<3 mcg/dL) or high (>20 mcg/dL). Since most patients will have serum cortisol levels in between these values, an ACTH stimulation test is usually needed to assess the adrenal function. This test should not delay starting treatment. In contrast to hydrocortisone, which interferes with the cortisol assay, leading to falsely normal serum cortisol, dexamethasone does not interfere with the testing and can be administered immediately and continued until the results of the test become available.
- Hyponatremia with low serum osmolality
- Because of decreased renal perfusion, serum creatinine levels are usually elevated
- Hypoglycemia is common and may also be caused by reduced nutrition, sepsis, or the associated adrenal insufficiency.
- Complete blood count: leukocytosis may not be seen because of hypothermia. A white blood cell differential may be one of the few clues to the presence of infection.
A diagnostic scoring system for the diagnosis of myxedema coma has been proposed. The scoring system gives points for the following indicators: hypothermia; lethargy, obtundation, stupor, or coma; anorexia, reduced intestinal mobility, or paralytic ileus; bradycardia, electrocardiogram changes, pericardial or pleural effusions, cardiomegaly or hypertension; hyponatremia, hypoglycemia, hypoxemia, hypercapnia or reduced glomerular filtration rate, and the presence of a precipitating cause. This scoring system was based on data derived from a small sample of 21 patients, which may limit its generalizability.
Chest X-ray may show signs of cardiomegaly, pericardial effusion, congestive heart failure, or pleural effusion.
Electrocardiogram may reveal sinus bradycardia, low-amplitude QRS complexes, a prolonged QT interval, flattened or inverted T waves, or arrhythmias.
Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med. 2007 Jul-Aug. 22(4):224-31. [Medline].
Klubo-Gwiezdzinska J, Wartofsky L. Thyroid emergencies. Med Clin North Am. 2012 Mar. 96(2):385-403. [Medline].
Waldman SA, Park D. Myxedema coma associated with lithium therapy. Am J Med. 1989 Sep. 87 (3):355-6. [Medline].
Mazonson PD, Williams ML, Cantley LK, Dalldorf FG, Utiger RD, Foster JR. Myxedema coma during long-term amiodarone therapy. Am J Med. 1984 Oct. 77 (4):751-4. [Medline].
Nicoloff JT, LoPresti JS. Myxedema coma. A form of decompensated hypothyroidism. Endocrinol Metab Clin North Am. 1993 Jun. 22(2):279-90. [Medline].
Klein I. Thyroid hormone and the cardiovascular system. Am J Med. 1990 Jun. 88 (6):631-7. [Medline].
Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006 Mar. 331 (3):154-6. [Medline].
Mathew V, Misgar RA, Ghosh S, Mukhopadhyay P, Roychowdhury P, Pandit K, et al. Myxedema coma: a new look into an old crisis. J Thyroid Res. 2011. 2011:493462. [Medline]. [Full Text].
Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV. Ventilatory control in myxedema and hypothyroidism. N Engl J Med. 1975 Mar 27. 292 (13):662-5. [Medline].
Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med. 1988 May. 84 (5):877-83. [Medline].
Ardalan MR, Ghabili K, Mirnour R, Shoja MM. Hypothyroidism-induced rhabdomyolysis and renal failure. Ren Fail. 2011. 33 (5):553-4. [Medline].
Birewar S, Oppenheimer M, Zawada ET Jr. Hypothyroid acute renal failure. S D J Med. 2004 Mar. 57 (3):109-10. [Medline].
Skowsky WR, Kikuchi TA. The role of vasopressin in the impaired water excretion of myxedema. Am J Med. 1978 Apr. 64 (4):613-21. [Medline].
Derubertis FR Jr, Michelis MF, Bloom ME, Mintz DH, Field JB, Davis BB. Impaired water excretion in myxedema. Am J Med. 1971 Jul. 51 (1):41-53. [Medline].
Bergeron E, Mitchell A, Heyen F, Dube S. Acute colonic surgery and unrecognized hypothyroidism: a warning. Report of six cases. Dis Colon Rectum. 1997 Jul. 40 (7):859-61. [Medline].
Ji JS, Chae HS, Cho YS, Kim HK, Kim SS, et al. Myxedema ascites: case report and literature review. J Korean Med Sci. 2006 Aug. 21 (4):761-4. [Medline].
Fukunaga K. Refractory gastrointestinal bleeding treated with thyroid hormone replacement. J Clin Gastroenterol. 2001 Aug. 33 (2):145-7. [Medline].
Manfredi E, van Zaane B, Gerdes VE, Brandjes DP, Squizzato A. Hypothyroidism and acquired von Willebrand's syndrome: a systematic review. Haemophilia. 2008 May. 14 (3):423-33. [Medline].
Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J. 1990 Apr. 66 (774):280-4. [Medline].
Rodriguez I, Fluiters E, Perez-Mendez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol. 2004 Feb. 180(2):347-50. [Medline]. [Full Text].
Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008. 12(1):R1. [Medline]. [Full Text].
Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid. 1999 Dec. 9(12):1167-74. [Medline].
Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh). 1985 Jan. 108(1):65-71. [Medline].
Jordan RM. Myxedema coma. Pathophysiology, therapy, and factors affecting prognosis. Med Clin North Am. 1995 Jan. 79(1):185-94. [Medline].
Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, et al. A diagnostic scoring system for myxedema coma. Endocr Pract. 2014 Aug 1. 20(8):808-17. [Medline].
MacKerrow SD, Osborn LA, Levy H, Eaton RP, Economou P. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med. 1992 Dec 15. 117 (12):1014-5. [Medline].
Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichaud J, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med. 1991. 17 (1):16-8. [Medline].
Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec. 24 (12):1670-751. [Medline].
Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine. Ann Intern Med. 1972 Oct. 77 (4):549-55. [Medline].
Fliers E, Wiersinga WM. Myxedema coma. Rev Endocr Metab Disord. 2003 May. 4(2):137-41. [Medline].
Dutta P, Bhansali A, Masoodi SR, Bhadada S, Sharma N, Rajput R. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care. 2008. 12(1):R1. [Medline]. [Full Text].